PURPOSE: Several reports have shown that proteasome levels may change during pathological processes. Here we investigated whether altered gene expression of the alpha-subunit of 20S proteasomes in leukocytes of glaucoma patients at the level of mRNA, shown by us earlier, is reflected by the level of protein synthesis. METHODS: Western blot analysis was performed to determine the protein levels of the 20S proteasome alpha-subunit in leukocytes of 12 glaucoma patients (6 HTG and 6 NTG) and 6 healthy controls. RESULTS: Plasma levels of the 20S proteasome alpha-subunit showed a 3.4+/-0.47 (mean+/-SD; p<0.0001) fold increase in glaucoma patients when compared to healthy controls. In addition, normal tension glaucoma patients revealed a more pronounced alpha-subunit expression (p<0.05) when compared to patients with high tension glaucoma. CONCLUSIONS: During the pathological process of glaucoma, proteasome protein levels increase. This indicates that proteasome protein levels may be a diagnostic or eventually a prognostic marker for glaucomatous damage.
PURPOSE: Several reports have shown that proteasome levels may change during pathological processes. Here we investigated whether altered gene expression of the alpha-subunit of 20S proteasomes in leukocytes of glaucomapatients at the level of mRNA, shown by us earlier, is reflected by the level of protein synthesis. METHODS: Western blot analysis was performed to determine the protein levels of the 20S proteasome alpha-subunit in leukocytes of 12 glaucomapatients (6 HTG and 6 NTG) and 6 healthy controls. RESULTS: Plasma levels of the 20S proteasome alpha-subunit showed a 3.4+/-0.47 (mean+/-SD; p<0.0001) fold increase in glaucomapatients when compared to healthy controls. In addition, normal tension glaucomapatients revealed a more pronounced alpha-subunit expression (p<0.05) when compared to patients with high tension glaucoma. CONCLUSIONS: During the pathological process of glaucoma, proteasome protein levels increase. This indicates that proteasome protein levels may be a diagnostic or eventually a prognostic marker for glaucomatous damage.
Authors: G R Tundo; D Sbardella; A M Santoro; A Coletta; F Oddone; G Grasso; D Milardi; P M Lacal; S Marini; R Purrello; G Graziani; M Coletta Journal: Pharmacol Ther Date: 2020-05-19 Impact factor: 12.310
Authors: Kristina Yeghiazaryan; Josef Flammer; Selim Orgül; Kerstin Wunderlich; Olga Golubnitschaja Journal: Mol Vis Date: 2009-11-14 Impact factor: 2.367
Authors: M Mozaffarieh; A Schoetzau; M Sauter; M Grieshaber; S Orgül; O Golubnitschaja; J Flammer Journal: Mol Vis Date: 2008-08-29 Impact factor: 2.367